Although the two groups were similar when it came to previous statin or antiplatelet treatment, history of diabetes mellitus, hypertension, tobacco use and previous coronary artery disease, it was observed that COVID-19-era patients had more frequent coronary thrombosis and a higher need of glycoproteins IIb/IIIa inhibitors treatment. The gene discussed is ART4; the disease is COVID-19.